Retatrutide already has the biggest weight reduction numbers of any compound on this site, and cagrilintide keeps coming up as something people wonder about adding to it. Before going further, here's the honest part. No one has published a trial combining these two, so nothing below is a result. It's reasoning, built from real data on each compound separately, and it's worth being upfront about which is which.
Four pathways is a different question than two
Retatrutide is a triple receptor agonist. It activates GLP-1 and GIP receptors, the same two tirzepatide targets, and adds a third, the glucagon receptor, which appears to independently drive energy expenditure and fat oxidation in the liver. That third pathway is a meaningful part of why retatrutide's Phase 2 data showed roughly 24% mean weight reduction over 48 weeks, among the largest ever recorded for an obesity compound. That number comes from Phase 2, and the ongoing Phase 3 program is what will actually settle retatrutide's approval path and its full safety profile, which matters on its own before anyone adds a second compound into the picture.
Cagrilintide works through amylin receptors, a pathway retatrutide doesn't touch at all. In the CagriSema trials, adding that amylin pathway to a single GLP-1 pathway (semaglutide) improved results over semaglutide alone. Layering the same amylin pathway onto a compound that's already working three separate receptors is a much bigger extrapolation than adding it to a single-receptor drug. Four active pathways at once isn't just "more of what worked before," it's a genuinely different pharmacological situation that hasn't been tested in a trial.
Why this pairing deserves more caution, not less
Retatrutide's glucagon component already means researchers have to think about heart rate and glucose effects that GLP-1-only compounds don't raise in the same way. Cagrilintide's amylin pathway brings its own gastrointestinal profile, similar in kind to what shows up with any GLP-1-adjacent compound but not identical. Nobody has published data on what these two side effect profiles look like layered together, and that's a real gap, not a technicality. It's the kind of thing a trial exists to answer, and until one does, anyone claiming to know the combined tolerability is speculating.
None of this means the idea is unreasonable. The same logic that made CagriSema worth testing, that amylin and incretin signaling are complementary rather than redundant, applies just as well here in principle. It just means retatrutide's own complexity makes this a pairing where the unknowns compound rather than one where you can lean on the semaglutide precedent and assume it transfers cleanly.
This is research information, not a treatment plan, and nothing here is a recommendation to combine anything. Whether to research this further, and whether to loop in a doctor who understands peptide research, is your call to make.
Where to go from here
For the sourced detail behind the numbers above, the Cagrilintide research notes and Retatrutide research notes pages carry the full citation list. The cagrilintide-plus-semaglutide piece covers the one combination that does have trial data, and the cagrilintide-plus-tirzepatide piece walks through the middle case between that precedent and this one.
We'll update this page the moment real trial data on this specific pairing exists. Until then, you can compare current cagrilintide and retatrutide pricing across vendors in the free tool.